Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition
Background: Uveal melanoma (UM) is an ocular malignancy with high potential for metastatic spread. In contrast to cutaneous melanoma, immunotherapy has not yet shown convincing efficacy in patients with UM. Combined immune checkpoint blockade with checkpoint programmed cell death-1 (PD-1) and checkp...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
22 June 2017
|
| In: |
European journal of cancer
Year: 2017, Jahrgang: 82, Pages: 56-65 |
| ISSN: | 1879-0852 |
| DOI: | 10.1016/j.ejca.2017.05.038 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1016/j.ejca.2017.05.038 Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S095980491731002X 
|
| Verfasserangaben: | Markus V. Heppt, Lucie Heinzerling, Katharina C. Kähler, Andrea Forschner, Michael C. Kirchberger, Carmen Loquai, Markus Meissner, Friedegund Meier, Patrick Terheyden, Beatrice Schell, Rudolf Herbst, Daniela Göppner, Felix Kiecker, David Rafei-Shamsabadi, Sebastian Haferkamp, Margit A. Huber, Jochen Utikal, Mirjana Ziemer, Irmgard Bumeder, Christiane Pfeiffer, Susanne G. Schäd, Christoph Schmid-Tannwald, Julia K. Tietze, Thomas K. Eigentler, Carola Berking |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1577857666 | ||
| 003 | DE-627 | ||
| 005 | 20240316100457.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180723s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejca.2017.05.038 |2 doi | |
| 035 | |a (DE-627)1577857666 | ||
| 035 | |a (DE-576)507857666 | ||
| 035 | |a (DE-599)BSZ507857666 | ||
| 035 | |a (OCoLC)1341014060 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Heppt, Markus V. |d 1987- |e VerfasserIn |0 (DE-588)1072242346 |0 (DE-627)827081111 |0 (DE-576)43371767X |4 aut | |
| 245 | 1 | 0 | |a Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition |c Markus V. Heppt, Lucie Heinzerling, Katharina C. Kähler, Andrea Forschner, Michael C. Kirchberger, Carmen Loquai, Markus Meissner, Friedegund Meier, Patrick Terheyden, Beatrice Schell, Rudolf Herbst, Daniela Göppner, Felix Kiecker, David Rafei-Shamsabadi, Sebastian Haferkamp, Margit A. Huber, Jochen Utikal, Mirjana Ziemer, Irmgard Bumeder, Christiane Pfeiffer, Susanne G. Schäd, Christoph Schmid-Tannwald, Julia K. Tietze, Thomas K. Eigentler, Carola Berking |
| 264 | 1 | |c 22 June 2017 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 23.07.2018 | ||
| 500 | |a Available online 22 June 2017 | ||
| 520 | |a Background: Uveal melanoma (UM) is an ocular malignancy with high potential for metastatic spread. In contrast to cutaneous melanoma, immunotherapy has not yet shown convincing efficacy in patients with UM. Combined immune checkpoint blockade with checkpoint programmed cell death-1 (PD-1) and checkpoint cytotoxic T-lymphocyte antigen-4 (CTLA-4) inhibition has not been systematically assessed for UM to date. Patients and methods: Patients with metastatic UM treated with either PD-1 inhibitor monotherapy or combined PD-1 inhibitor and ipilimumab (an anti-CTLA-4 monoclonal antibody) were included from 20 German skin cancer centres. Records from 96 cases were analysed for treatment outcomes. Clinical and blood parameters associated with overall survival (OS) or treatment response were identified with multivariate Cox regression and binary logistic regression. Results: Eighty-six patients were treated with PD-1 inhibitors only (n = 54 for pembrolizumab, n = 32 for nivolumab) with a centrally confirmed response rate of 4.7%. Median OS was 14 months for pembrolizumab-treated and 10 months for nivolumab-treated patients (p = 0.765). Fifteen patients were treated with combined immune checkpoint blockade with partial response observed in two cases. Median OS was not reached in this group. Multivariate Cox regression identified Eastern Cooperative Oncology Group (ECOG) performance status (p = 0.002), elevated serum levels of lactate dehydrogenase (LDH) (p = 0.002) and C-reactive protein (CRP) (p = 0.001), and a relative eosinophil count (REC) <1.5% (p = 0.002) as independent risk factors for poor survival. Patients with elevated CRP and LDH and a REC <1.5% were at highest risk for disease progression and death (p = 0.001). Conclusions: Blood markers predict survival in metastatic UM treated with immune checkpoint blockade. Normal serum levels of LDH and CRP and a high REC may help identify patients with better prognosis. | ||
| 650 | 4 | |a Biomarker | |
| 650 | 4 | |a Immune checkpoint blockade | |
| 650 | 4 | |a Ipilimumab | |
| 650 | 4 | |a Nivolumab | |
| 650 | 4 | |a Pembrolizumab | |
| 650 | 4 | |a Uveal melanoma | |
| 700 | 1 | |a Utikal, Jochen |d 1974- |e VerfasserIn |0 (DE-588)1026463750 |0 (DE-627)726765015 |0 (DE-576)371816580 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of cancer |d Amsterdam [u.a.] : Elsevier, 1992 |g 82(2017), Seite 56-65 |w (DE-627)266883400 |w (DE-600)1468190-0 |w (DE-576)090954173 |x 1879-0852 |7 nnas |a Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition |
| 773 | 1 | 8 | |g volume:82 |g year:2017 |g pages:56-65 |g extent:10 |a Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejca.2017.05.038 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S095980491731002X |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180723 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 1026463750 |a Utikal, Jochen |m 1026463750:Utikal, Jochen |d 60000 |e 60000PU1026463750 |k 0/60000/ |p 17 | ||
| 999 | |a KXP-PPN1577857666 |e 3019383056 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"origin":[{"dateIssuedDisp":"22 June 2017","dateIssuedKey":"2017"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"person":[{"display":"Heppt, Markus V.","role":"aut","given":"Markus V.","roleDisplay":"VerfasserIn","family":"Heppt"},{"roleDisplay":"VerfasserIn","family":"Utikal","role":"aut","display":"Utikal, Jochen","given":"Jochen"}],"name":{"displayForm":["Markus V. Heppt, Lucie Heinzerling, Katharina C. Kähler, Andrea Forschner, Michael C. Kirchberger, Carmen Loquai, Markus Meissner, Friedegund Meier, Patrick Terheyden, Beatrice Schell, Rudolf Herbst, Daniela Göppner, Felix Kiecker, David Rafei-Shamsabadi, Sebastian Haferkamp, Margit A. Huber, Jochen Utikal, Mirjana Ziemer, Irmgard Bumeder, Christiane Pfeiffer, Susanne G. Schäd, Christoph Schmid-Tannwald, Julia K. Tietze, Thomas K. Eigentler, Carola Berking"]},"physDesc":[{"extent":"10 S."}],"relHost":[{"id":{"issn":["1879-0852"],"zdb":["1468190-0"],"eki":["266883400"]},"title":[{"title_sort":"European journal of cancer","title":"European journal of cancer"}],"disp":"Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibitionEuropean journal of cancer","note":["Gesehen am 21.03.24","Ungezählte Beil.: Supplement"],"origin":[{"publisher":"Elsevier ; Pergamon Press","dateIssuedDisp":"1992-","dateIssuedKey":"1992","publisherPlace":"Amsterdam [u.a.] ; [Erscheinungsort nicht ermittelbar]"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"part":{"volume":"82","text":"82(2017), Seite 56-65","pages":"56-65","extent":"10","year":"2017"},"recId":"266883400","titleAlt":[{"title":"EJC online"}],"pubHistory":["28.1992 -"],"corporate":[{"roleDisplay":"Herausgebendes Organ","role":"isb","display":"European Organization for Research on Treatment of Cancer"},{"display":"European Association for Cancer Research","role":"isb","roleDisplay":"Herausgebendes Organ"},{"roleDisplay":"Herausgebendes Organ","role":"isb","display":"European School of Oncology"}]}],"id":{"doi":["10.1016/j.ejca.2017.05.038"],"eki":["1577857666"]},"title":[{"title_sort":"Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition","title":"Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition"}],"recId":"1577857666","note":["Gesehen am 23.07.2018","Available online 22 June 2017"]} | ||
| SRT | |a HEPPTMARKUPROGNOSTIC2220 | ||